A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan

• Conditions: Congenital Bleeding Disorder; Congenital FXIII Deficiency
• Interventions: Drug: recombinant factor XIII

• Registration Number: NCT02670213
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This study is conducted in Asia. Tha aim of this study is to investigate Safety and Effectiveness of NovoThirteen® (rFXIII) during treatment of congenital FXIII deficiency in Japan.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2016-01-28
• Study First Submitted QC: 2016-01-28
• Study First Posted: 2016-02-01
• Study Start: 2016-03-16
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-27
• Last Update Posted: 2023-11-28
• Primary Completion: 2024-09-30
• Study Completion: 2024-09-30

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

• Male of female patients, regardless of age, requiring treatment with NovoThirteenR for whom the treating physician has decided to use NovoThirteenR (rFXIII) treatment

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
NovoThirteen®	recombinant factor XIII	-

Primary Outcome Measures

Name	Time	Method
Adverse drug reactions in patients with congenital FXIII A-subunit deficiency treated with NovoThirteen®, comprising FXIII antibodies, allergic reactions, embolic and thrombotic events and lack of therapeutic effect	Year 0-9

Secondary Outcome Measures

Name	Time	Method
All technical complaints	Year 0-9
Frequency of bleeding episodes	Year 0-9
All serious adverse events	Year 0-9
All adverse events	Year 0-9
All medical event of special interest	Year 0-9
All medication errors collected	Year 0-9
Use of NovoThirteen® for other uses than for the approved indication	Year 0-9

Trial Locations

Locations (1)

Novo Nordisk Investigational Site; 🇯🇵 Tokyo, Japan